Nektar Therapeutics (NKTR) earnings
In the quarter ended June 2026, Nektar Therapeutics had revenue of $10M, down 9.3% on a year earlier, and diluted EPS of -1.23.
On August 13, 2026 it reported EPS of -1.23 against an estimate of -2.06 (beat).
The next report is expected on Thursday, November 5, 2026, with EPS expected around -2.20.
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Next | Thu Nov 5, 2026 | — | -2.20 | — |
| Last | Thu Aug 13, 2026 | — | -2.06 | -1.23 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from Nektar Therapeutics's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $10M | -9.3% | -1.23 | — | -417.9% | 2026-08-14 |
| Mar 31, 2026 | $11M | +3.8% | -1.82 | — | -359.6% | 2026-05-08 |
| Dec 31, 2025 | $22M | -25.3% | — | — | -126.9% | 2026-03-13 |
| Sep 30, 2025 | $12M | -51.1% | -1.87 | — | -268.6% | 2025-11-07 |
| Jun 30, 2025 | $11M | -52.4% | -2.95 | — | -324.2% | 2025-08-08 |
| Mar 31, 2025 | $10M | -51.7% | -3.62 | — | -425.8% | 2025-05-09 |
| Dec 31, 2024 | $29M | +22.1% | — | — | 49.2% | 2025-03-14 |
| Sep 30, 2024 | $24M | -0.1% | -2.66 | — | -142.4% | 2024-11-08 |
| Jun 30, 2024 | $23M | +14.6% | -3.76 | — | -211.9% | 2024-08-09 |
| Mar 31, 2024 | $22M | +0.2% | -2.85 | — | -163.7% | 2024-05-10 |
| Dec 31, 2023 | $24M | +8.5% | — | — | -140.3% | 2024-03-05 |
| Sep 30, 2023 | $24M | +2.2% | -3.60 | — | -185.8% | 2023-11-08 |
Questions
When does Nektar Therapeutics report earnings?
Nektar Therapeutics's next earnings report is expected on November 5, 2026.
How did Nektar Therapeutics do last quarter?
In the quarter ended June 2026, Nektar Therapeutics had revenue of $10M, down 9.3% on a year earlier, and diluted EPS of -1.23.
From Nektar Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.